GIA
ORMP icon

Gem Investment Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Gem Investment Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.61M Buy
1,998,802
+358,733
+22% +$1.43M 5.89% 5
2026
Q1 		$5.58M Sell
1,640,069
-358,733
-18% -$1.22M 5.48% 6
2025
Q4 		$5.7M Buy
+1,998,802
New +$5.16M 5.4% 7

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Gem Investment Advisors's ORMP Position: Q2 2026 in Review

Gem Investment Advisors increased its Oramed Pharmaceuticals (ORMP) stake by 22% in Q2 2026, buying an estimated $1.43M and bringing the position to 1,998,802 shares worth $9.61M. The position accounts for 5.89% of the portfolio, ranked #5.

Gem Investment Advisors first reported a position in ORMP in Q4 2025 and has held it in 3 quarters since. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Gem Investment Advisors held 1,998,802 shares of Oramed Pharmaceuticals worth $9.61M as of Q2 2026.
  • Gem Investment Advisors bought 358,733 Oramed Pharmaceuticals shares in Q2 2026, an estimated $1.43M.
  • Oramed Pharmaceuticals made up 5.89% of Gem Investment Advisors's portfolio in Q2 2026, its #5 holding.
  • Gem Investment Advisors first reported a position in Oramed Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Gem Investment Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.